|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that IL-28B T allele affects the natural course of CHC type 4 and also suggests that carriage of the IL-28B C allele protects from unfavorable clinical outcomes in CHC as coexistence of C allele with T allele reduced cirrhosis severity.
|
29893697 |
2019 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Binary logistic regression was used to study the impact of cirrhosis, anti-HCV therapy experience and the IL28B polymorphism on SVR, besides factors with a p value < 0.15 from the univariate analysis.DAA were prescribed to 423 patients.SVR was confirmed in 92.9%.
|
30687869 |
2019 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL-28B rs12979860 TT genotype is more prevalent in patients with advanced fibrosis, cirrhosis and HCC stages.
|
29914308 |
2018 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis in overall patients revealed that cirrhosis (HR: 2.94, 95% CI: 1.81-4.77, p < 0.001), IL28B rs12979860 (CT + TT) polymorphisms (HR: 3.22, 95% CI: 2.17-4.78, p < 0.001), and high APRI levels (≥2.57) (HR: 2.32, 95% CI: 1.47-3.67, p < 0.001) were independent risk factors for HCC.
|
29254684 |
2018 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to determine whether IL28B rs12979860 polymorphism is also associated with development of hepatocellular carcinoma both in chronic HCV infection and in non-viral-related cirrhosis.
|
27083168 |
2017 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of this study suggest that IL28B rs12979860 TT or rs12980275 GG may play an important protective role against the development of advanced fibrosis and even cirrhosis.
|
28253210 |
2017 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Serum miR-126, miR-129, miR-203a, and miR-223 were upregulated in severe fibrosis (≥F3) and cirrhosis (F4) compared with F0-F2 and F0-F3, respectively. miR-221 was upregulated in ≥F3, but unchanged in F4. miR-155, miR-199a, and IFNL3 rs12979860 genotype were not significantly different in all comparisons.
|
28211229 |
2017 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wild type haplotype (TLR2 ins/ins- IL28B C/C) was also found associated with older age in patients with an hepatic diseases (in CIR and in HCC p = 0.038 and p = 0.020, respectively) supporting an effect of innate immunity in the liver disease progression.
|
27183918 |
2016 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated independent variables such as age, with or without cirrhosis, prior treatment response to interferon (IFN) therapy, IL28B genotype, core amino acid (aa) 70 mutation, drug adherence, white blood cell counts, hemoglobin level, and serum low-density lipoprotein (LDL) cholesterol level.
|
26732192 |
2016 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SVR12 by baseline factors including age, viral load, interleukin-28B genotype and cirrhosis status was similar between the Asian sub-cohorts.
|
27009831 |
2016 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned (2:1) to daclatasvir vs telaprevir, stratified by IL28B rs12979860 host genotype (CC vs non-CC), cirrhosis status (compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype (GT1a vs GT1b).
|
27022224 |
2016 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
At week 4, low HCV RNA, absence of cirrhosis and IL28B CC were associated with <LLOQ, TND.
|
26891418 |
2016 |
|
Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Within the various disease stages, compared to IC and healthy controls, IL28B expression was reduced in the CHB, cirrhosis, and HCC cohorts (CHB vs. IC, p=0.02; cirrhosis vs. IC, p=0.01; HCC vs. IC, p=0.001; CHB vs. controls, p<0.01; cirrhosis vs. controls, p<0.01; HCC vs. controls, p<0.01).
|
25837166 |
2015 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with HCV genotype 1 (HCV-1), a PEG-IFN/RBV-based regimen with sofosbuvir is highly effective but the presence of cirrhosis and the non-CC IFNL3 genotype have been associated with a poorer response.
|
25529083 |
2015 |
|
Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Also, patients who were presented with cirrhosis (Cirr) only or with cirrhosis plus hepatocellular carcinoma (Cirr+HCC) had higher levels of serum IL28B when compared to chronic HCV-infected patients (P = 0.005 and 0.003, resp.).
|
25811035 |
2015 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The standard of care for the treatment of HCV-related cirrhosis with interferon-α plus ribavirin should consider the genotypes of IL-28B.
|
24914367 |
2014 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In comparison with TVR-based strategies, SOF was cost-effective in IL28B CT/TT (ICER per LYG € 22,229) and G1a (€ 19,359) patients, not cost-effective in IL28B CC (€45,330), fibrosis F0-F3 (€ 26,444), and in cirrhosis (€ 34,906) patients, and dominated in G1b patients.
|
24691835 |
2014 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
At baseline, of 740 patients, 85% had levels of HCV RNA ≥800,000 IU/mL, 28% had fibrosis (F3-F4), 14% had cirrhosis (F4), 57% were infected with HCV genotype 1a, and 71% had the non-CC IL28B genotype.
|
24316262 |
2014 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.
|
25504078 |
2014 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariable analysis identified four independent factors that were significantly associated with SVR: IL28B SNP rs8099917 genotype (P = 6.90 × 10(-5) ), pre-existence of cirrhosis (P = 3.99 × 10(-3) ), prior treatment response (P = 0.0126), and rapid virological response (P = 0.0239).
|
24117654 |
2014 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
109 HCV-1 IL28B CC were studied.Sixty were males, 39 with BMI >25, 69 with >600,000 IU/mL HCV RNA, 15 with HCV1a, and 30 with cirrhosis.
|
23936821 |
2013 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
VR rates were higher in arms A-D than in arm E at weeks 4 and 12 overall, in patients with and without cirrhosis and in patients with CC and non-CC IL28B genotypes.
|
23348636 |
2013 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In week-8 viral response patients, the SVR rates of 72-week and 48-week treatment were similar (75-88%), regardless of IL28B SNP genotypes or cirrhosis.
|
22898703 |
2012 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low baseline viral load, IL28B genotype CC and absence of cirrhosis were statistically associated with SVR.
|
22670704 |
2012 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
|
23145809 |
2012 |